Table 1 Published clinical trials evaluating ICIs in virus-related cancers
From: Immune checkpoint inhibitors in the treatment of virus-associated cancers
Viruses | ICIs | Cancers | Response rates | Ref. |
|---|---|---|---|---|
HPV | Pembrolizumab | R/M cervical cancer | 17% | [12] |
Nivolumab | GYN cancers | 20.8% | [13] | |
Nivolumab | SCCA | 24% | [14] | |
Pembrolizumab | R/M HNSCC | 18% | [15] | |
HPV-positive | 25% | |||
HPV-negative | 14% | |||
Durvalumab | R/M HNSCC | 16.2% | [16] | |
HPV-positive | 29.4% | |||
HPV-negative | 10.8% | |||
HBV/HCV | Nivolumab | HCV infection | 11.1% | [17] |
Tremelimumab | HCC | 17.6% | [18] | |
Tremelimumab | HCC | 26.3% | [19] | |
Nivolumab | HCC | 15%-20% | [20] | |
HBV/HCV-positive | 14-20% | |||
HBV/HCV-negative | 21-23% | |||
EBV | Nivolumab | R/M NPC | 20.5% | [21] |
Pembrolizumab | R/M NPC | 25.9% | [22] | |
Pembrolizumab | NK/T cell lymphoma | 71.4% | [23] | |
Pembrolizumab | NHL | 23.3% | [24] | |
Pembrolizumab | EBV-positive GC | 100% | [25] | |
Nivolumab | EBV-negative GC | 25% | [26] | |
HIV | Nivolumab | Cancer (HIV-positive) | 27%-63% | [27] |
Ipilimumab | ||||
HTLV-1 | Adult T cell lymphoma | |||
HHV-8 | Kaposi’s sarcoma |